Drug Profile
Research programme: microRNA therapeutics - Viridian Therapeutics
Alternative Names: AntimiR-15; AntimiR-155; AntimiR-208; AntimiRNA-15; LNA antimiR; MGN 7455; MGN-4893; mimics of the microRNA-183/96/182 - Viridian Therapeutics; miR-143/145; miR-15/195; miR-206; miR-208; miR-208/499; miR-29; miR-499; miR-92/126; miR-92a; MIRG-9103; miRNA-145 inhibitor; MRG-107Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer miRagen Therapeutics; Servier; University of Glasgow; University of Texas Southwestern Medical Center; Viridian Therapeutics
- Class Cardiovascular therapies; Eye disorder therapies; MicroRNAs; Neuroprotectants
- Mechanism of Action MicroRNA inhibitors; MIRN145-microRNA-inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Cardiovascular disorders; Heart failure; Hypertrophic cardiomyopathy; Ischaemia; Postmyocardial infarction; Retinal disorders
- Discontinued Coronary artery restenosis; Fibrosis; Polycythaemia vera; Pulmonary arterial hypertension
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Parenteral)
- 19 Jan 2021 miRagen Therapeutics is now called Viridian Therapeutics
- 28 Jul 2020 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)